Equities analysts expect Horizon Therapeutics PLC (NASDAQ:HZNP) to post earnings of $0.39 per share for the current quarter, according to Zacks. Three analysts have provided estimates for Horizon Therapeutics’ earnings, with the highest EPS estimate coming in at $0.41 and the lowest estimate coming in at $0.37. Horizon Therapeutics posted earnings per share of $0.48 in the same quarter last year, which would suggest a negative year over year growth rate of 18.8%. The company is expected to report its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Horizon Therapeutics will report full-year earnings of $1.74 per share for the current year, with EPS estimates ranging from $1.58 to $1.86. For the next fiscal year, analysts anticipate that the business will report earnings of $2.05 per share, with EPS estimates ranging from $1.80 to $2.29. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Horizon Therapeutics.
Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.20. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The company had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. During the same period last year, the firm earned $0.03 earnings per share. The firm’s revenue was up 25.0% on a year-over-year basis.
A number of research firms recently weighed in on HZNP. Cantor Fitzgerald raised their price target on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Piper Jaffray Companies set a $195.00 price target on shares of Cummins and gave the company a “buy” rating in a research report on Thursday, April 4th. Citigroup raised their price target on shares of Martin Marietta Materials from $239.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. BMO Capital Markets set a $13.00 price objective on shares of Vale and gave the stock a “hold” rating in a report on Thursday, April 4th. Finally, Mizuho set a $27.00 price objective on shares of Horizon Therapeutics and gave the stock a “hold” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $31.91.
HZNP opened at $23.46 on Tuesday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.74 and a quick ratio of 1.68. The firm’s 50-day moving average price is $23.99. Horizon Therapeutics has a fifty-two week low of $16.56 and a fifty-two week high of $29.44. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 12.82, a P/E/G ratio of 1.35 and a beta of 1.03.
In related news, insider Jeff Kent sold 3,620 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total transaction of $89,196.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vikram Karnani sold 13,111 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $25.02, for a total transaction of $328,037.22. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Regent Investment Management LLC increased its stake in shares of Horizon Therapeutics by 71.7% in the first quarter. Regent Investment Management LLC now owns 90,150 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 37,660 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Horizon Therapeutics by 1.5% in the fourth quarter. First Trust Advisors LP now owns 202,743 shares of the biopharmaceutical company’s stock worth $3,962,000 after purchasing an additional 3,052 shares in the last quarter. LPL Financial LLC purchased a new position in shares of Horizon Therapeutics in the fourth quarter worth about $504,000. Signition LP purchased a new position in shares of Horizon Therapeutics in the first quarter worth about $232,000. Finally, Granite Investment Partners LLC purchased a new position in shares of Horizon Therapeutics in the fourth quarter worth about $915,000. Institutional investors and hedge funds own 87.79% of the company’s stock.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.